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modifies fasting total cholesterol
concentrations in response to replacement
of dietary saturated with monounsaturated
fatty acids in adults at moderate
cardiovascular disease risk
Israa M. Shatwan1,2, Michelle Weech1, Kim G. Jackson1, Julie A. Lovegrove1 and Karani S. Vimaleswaran1*Abstract
Background: Consumption of ≤10% total energy from fat as saturated fatty acids (SFA) is recommended for
cardiovascular disease risk reduction in the UK; however there is no clear guidance on the optimum replacement
nutrient. Lipid-associated single-nucleotide polymorphisms (SNPs) have been shown to modify the lipid responses
to dietary fat interventions. Hence, we performed a retrospective analysis in 120 participants from the Dietary
Intervention and VAScular function (DIVAS) study to investigate whether lipoprotein lipase (LPL) and apolipoprotein
E (APOE) SNPs modify the fasting lipid response to replacement of SFA with monounsaturated (MUFA) or n-6
polyunsaturated (PUFA) fatty acids.
Methods: The DIVAS study was a randomized, single-blinded, parallel dietary intervention study performed in
adults with a moderate cardiovascular risk who received one of three isoenergetic diets rich in SFA, MUFA or n-6
PUFA for 16 weeks.
Results: After the 16-week intervention, a significant diet-gene interaction was observed for changes in fasting total
cholesterol (P= 0.001). For the APOE SNP rs1064725, only TT homozygotes showed a significant reduction in total cholesterol
after the MUFA diet (n= 33; −0.71 ± 1.88 mmol/l) compared to the SFA (n= 38; 0.34 ± 0.55 mmol/l) or n-6 PUFA diets
(n= 37; −0.08 ± 0.73 mmol/l) (P= 0.004). None of the interactions were statistically significant for the other SNPs.
Conclusions: In summary, our findings have demonstrated a greater sensitivity of the APOE SNP rs1064725 to dietary fat
composition, with a total cholesterol lowering effect observed following substitution of SFA with MUFA but not n-6 PUFA.
Further large intervention studies incorporating prospective genotyping are required to confirm or refute our findings.
Trial registration: The trial was registered at www.clinicaltrials.gov as NCT01478958.
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A high consumption of saturated fatty acids (SFA) has
been linked to increased circulating concentrations of
low-density lipoprotein cholesterol (LDL-C) [1], and is
consequently associated with an increased cardiovascular
disease (CVD) risk [2]. Therefore, dietary guidelines have
focused on reducing intakes of SFA by ≤10% of total en-
ergy (TE) for CVD risk reduction [3]. It is important to
consider the nutrients that replace SFAs and previous
findings have suggested substitution of SFA with unsatur-
ated fatty acids may provide a greater reduction in CVD
risk than refined carbohydrates [4, 5]. In particular, re-
placement with cis-monounsaturated fatty acids (MUFA)
or polyunsaturated fatty acids (PUFA) has been shown to
significantly lower fasting total and LDL-C [6, 7]. How-
ever, the inter-individual variability in fasting plasma lipid
responses to dietary fat intake is high; evidence supports
that this is influenced by lipid-associated single-nucleotide
polymorphisms (SNPs) such as apolipoprotein E (APOE)
and lipoprotein lipase (LPL) genotypes [8–10].
Several genes are involved in the regulation of lipid trans-
port and metabolism [11]. Among these, the most com-
monly studied genes with central roles in lipid metabolism
are LPL and APOE [12–14]. The LPL SNPs, rs320 (HindIII)
and rs328 (S447X), have been proposed as important gen-
etic determinants of the inter-individual variability in fast-
ing and postprandial triacylglycerol (TAG) concentrations
and high-density lipoprotein cholesterol (HDL-C) [15–17].
Increased activity of the LPL enzyme in minor allele car-
riers of LPL SNP rs328 has been shown to be associated
with lower plasma TAG and higher HDL-C levels [18]. To
date, there has only been one study reporting an interaction
between LPL rs328 and n-6 PUFA intake on fasting TAG
concentrations [19]. The effect of genetic variations of
APOE on lipid concentrations (i.e. LDL-C) [20–23] and the
effect of the APOE polymorphisms on the circulating lipid
response to dietary fat (i.e. SFA and MUFA) have been
previously demonstrated; however, the findings have been
inconsistent [24–26]. In addition, investigations into other
SNPs of the APOE gene are limited.
In the Dietary Intervention and VAScular function (DI-
VAS) study, the isoenergetic replacement of 9.5–9.6% TE
from SFA with cis MUFA or n–6 PUFA for 16 weeks in
195 adults at moderate CVD risk resulted in significant re-
ductions of 8.4% and 9.2%, respectively, in total cholesterol,
and 11.3% and 13.6%, in LDL-C, in the fasted state [6]. To
investigate whether genetic polymorphisms contributed to
the observed reductions in total and LDL-C, a retrospect-
ive post hoc analysis of the DIVAS study was performed.
We examined whether the two LPL and seven tagging
SNPs (TagSNPs) in the APOE gene modified the response
of the fasting lipid profile to substitution of SFA with
MUFA or n-6 PUFA in this study population at moderate
CVD risk.Participants and methods
Study participants
A detailed description of the DIVAS study design and
methods has been reported elsewhere [6, 27]. Briefly,
participants were recruited from Reading, UK and the
surrounding area in three cohorts between November
2009 and July 2012. Participants were aged between 21 and
60 years and were all non-smoking men and women with a
moderate risk of CVD. A scoring tool [27] was used to
determine CVD risk based on the presence of single or
multiple risk factors, including elevated fasting total chol-
esterol or fasting glucose, raised blood pressure, low HDL-
C, being overweight or obese, and/or having a family his-
tory of premature myocardial infarction or type 2 diabetes.
Eligible participants had a risk score of ≥ 2 combined
points, reflecting a moderate CVD risk (≥50% above the
population mean). Other criteria for exclusion were the
presence of abnormal fasting blood biochemistry, taking
dietary supplements or the use of medications that affect
lipid metabolism or hypertension, and having inflammatory
disorders. The West Berkshire Local Research ethics com-
mittee (09/ H0505/56) and the University of Reading Re-
search Ethics Committee (09/40) gave a favourable ethical
opinion for conduct. The trial was registered at www.clini-
caltrials.gov as NCT01478958. All participants provided
written informed consent before participating. In our
retrospective analysis, 120 of the 195 participants who
completed the DIVAS study consented to genetic analysis,
and were included in the present study.
Study design and diets
The DIVAS study was a randomized, single-blinded, parallel
design. The participants completed 16 weeks of dietary inter-
vention, receiving one of three isoenergetic diets based on a
minimization program that matched for age, sex, body mass
index (BMI), and total CVD risk score. The three interven-
tion diets (%TE derived from SFA:MUFA:n-6 PUFA) were
either rich in SFAs (17:11:4), MUFAs (9:19:4), or n-6 PUFAs
(9:13:10). Given that dietary guidelines recommend limiting
n-6 PUFA intake to ≤10% TE [28], SFA were replaced with
6% TE n-6 PUFA and 2% TE MUFA in the n-6-PUFA-rich
diet. The total fat content of all three intervention diets was
36% TE, and intakes of protein, carbohydrates, and n-3
PUFA were unchanged. A greater SFA exchange than the
target 8% TE was achieved: SFA vs MUFA was 9.5% TE and
SFA vs n-6 PUFA was 9.6% TE [27].
Further details of the dietary intervention procedure and
measures of compliance have been published previously [27].
In summary, these interventions were based on a flexible
food-exchange model to achieve the target fatty acid intakes
in free-living individuals for 16 weeks. Participants, who were
randomly assigned to one of three intervention diets, re-
placed routinely consumed sources of exchangeable fats with
study foods. The study foods included spreads, oils, dairy
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acid composition. Specially formulated spreads (80% total fat)
and oils (Unilever Research and Development) were used for
the MUFA-rich diet (refined olive oil and olive oil/rapeseed
oil blended spread) and n–6 PUFA-rich diet (safflower oil
and spread). Butter (Wyke Farm) was used as both a spread
and oil replacement in the SFA-rich diet.
Anthropometric measurements and biochemical parameters
Clinical visits took place at the Hugh Sinclair Unit of
Human Nutrition, University of Reading, during weeks 0
(baseline; V1) and 16 (after intervention; V2) as described
elsewhere [6]. Alcohol and aerobic exercise were avoided
24 h before visits. Participants consumed a provided low-
fat meal the evening before visits and fasted for 12 h, only
drinking low-nitrate water during this time. Height and
weight was recorded at the study visits at weeks 0 and 16 in
order to calculate BMI. Height was recorded to the nearest
0.5 cm using a wall-mounted stadiometer and weight was
measured using a digital scale (Tanita Europe) using stand-
ard settings (normal body type and 1 kg for clothing).
At weeks 0 and 16, fasting blood samples collected into
a serum separator vacutainer and a K3EDTA-containing
vacutainer (week 0 only) were used for the measurement
of the fasting lipid profile and isolation of the buffy coat,
respectively. The K3EDTA-containing vacutainer was kept
on ice for 30 min before the blood tubes were centrifuged
at 1700 g for 15 min at 20 °C (for serum) and 4 °C (for
plasma). The buffy coat was stored at −20 °C and serum
samples stored at −80 °C prior to analysis of total choles-
terol, TAG, and HDL-C, and glucose (baseline only) con-
centrations using an autoanalyzer (reagents and analyzer:
Werfen UK Ltd). Fasting LDL-C was estimated using the
Friedewald formula [29]. With the use of A/A grade auto-
mated oscillometric ambulatory blood pressure (ABP)
monitors (A&D Instruments Ltd.), baseline 24 h ABP was
measured every 30 min from 07:00 to 21:59 and every
60 min from 22:00 to 06:59, approximately 48 h before the
clinical visits.
SNP selection and genetic analysis
The APOE gene is located on chromosome 19q13.32 and
comprises of four exons, which are transcribed into the
1180 nucleotides long APOE mRNA. The seven tagSNPs
for the APOE gene were chosen based on International
HapMap Phase II collected in individuals of Northern and
Western European ancestry (CEU) (HapMap Data release
27 Phase 2 + 3, Feb 09, NCBI B36 assembly, dbSNP b126).
The Haploview software V3.3 (https://www.broadinstitute.
org/haploview/haploview) was used to assess the linkage
disequilibrium structure between SNPs. Tagger software
was used to select tag SNPs with the ‘pairwise tagging
only’ option. Two criteria were used to filter the SNPs in-
cluded in the analysis - minor allele frequency ≥ 5% andHardy–Weinberg equilibrium P-value >0.01. Seven
tagSNPs (rs405509 (G > T) [30, 31], rs1160985 (C > T)
[32], rs769450 (G > A) [33], rs439401 (C > T) [34],
rs445925 (G > A) [35], rs405697 (G >A) [36], and
rs1064725 (T >G)) representing the entire common gen-
etic variations across the APOE gene were selected for the
study. In addition, the two commonly studied LPL SNPs,
rs320 and rs328, were chosen. In total, nine common
SNPs were examined in the present study.
DNA was extracted from the buffy coat using a QIAamp
DNA blood kit (QIAGEN) and stored at −20 °C. The
genotyping of the LPL and APOE SNPs was outsourced
to LGC Genomics (http://www.lgcgroup.com/services/
genotyping), which employs the competitive allele-specific
PCR-KASP® assay.
Statistical analysis
The data are presented as mean ± standard deviation (SD)
in the tables and text, and as standard error in the figure.
The normal distribution was tested for variables, and none
of the variables skewed the distribution. The minor allele
frequency was calculated by counting. The dominant
models were a better fit for SNPs rs320, rs328, rs769450,
rs439401, rs445925, rs405697, and rs1064725; thus, homo-
zygosity for the common allele was compared with carriers
of the minor allele (heterozygous and homozygous for the
minor allele) in the analysis. The additive model was
applied for SNPs rs405509 and rs1160985 (major allele
homozygotes vs. heterozygotes vs. minor allele homozy-
gotes). The genotype distributions of the nine SNPs at the
LPL and APOE genes were in Hardy-Weinberg equilibrium
(P > 0.05). Independent t-tests were used to compare means
between men and women at baseline. The baseline and
over 16 weeks’ associations of the selected SNPs with con-
tinuous phenotypes were evaluated by the general linear
model (GLM). Moreover, potential interactions between
genotype and dietary intervention on 16-week changes of
lipids were analyzed by using GLM, where an interaction
term was included in the model. Potential confounders as-
sociated with the outcomes were adjusted in all GLM ana-
lyses (i.e. age, sex, BMI, and ethnicity). When a significant
diet x genotype interaction was found, data were split by
genotype group and analyzed further by using GLM. A
Bonferroni correction was applied and the significant
P value was 0.0013 (0.05/9 SNPs*4 lipid outcomes). For all
analyses, the statistical package SPSS version 22.0 (SPSS,
Chicago, IL, USA) was used.
Results
In this retrospective analysis, 120 participants (mean age,
47 ± 9 years; BMI, 26.4 ± 4.0 kg/m2) were included. Table 1
illustrates the main characteristics of the study partici-
pants stratified according to sex at baseline. Women had
significantly lower levels of fasting TAG (P < 0.0001),
Table 1 Baseline characteristics of study participants in the whole group and stratified by sex
Characteristics Whole group (N = 120) Men (N = 54) Women (N = 66) P value
Age 47 ± 9 48 ± 9 46 ± 9 0.37
BMI 26.3 ± 3.9 26.7 ± 3.6 26.2 ± 4.3 0.58
Systolic blood pressure 122 ± 10 126 ± 9 120 ± 9 0.01
Diastolic blood pressure 75 ± 7 77 ± 7 74 ± 7 0.03
Total cholesterol 5.58 ± 1.11 5.75 ± 1.15 5.45 ± 1.06 0.16
TAG 1.28 ± 0.60 1.62 ± 0.61 1.02 ± 0.44 <0.0001
HDL-C 1.54 ± 0.35 1.36 ± 0.32 1.68 ± 0.32 <0.0001
LDL-C 3.79 ± 0.99 4.06 ± 1.01 3.57 ± 0.93 0.01
Glucose 5.11 ± 0.42 5.23 ± 0.44 5.03 ± 0.39 0.02
Data shown are represented as means ± SD, wherever appropriate. P values for the differences in the means between men and women. P values were calculated
by using independent t-test
BMI body mass index, TAG triacylglycerol, HDL-C high- density lipoprotein cholesterol, LDL-C low- density lipoprotein cholesterol
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0.03), and higher levels of fasting HDL-C (P < 0.0001)
compared to men.
The genotype distributions of both LPL and APOE
polymorphisms are shown in Table 2. The participants’
characteristics at the beginning of the dietary interven-
tions (week 0) are presented in Table 3 according to LPL
and APOE genotypes. None of the variables (including
fasting TAG, total cholesterol, LDL-C, and HDL-C) were
associated with the LPL and APOE SNPs at baseline.
After 16 weeks of intervention, there was also no signifi-
cant association of the LPL and APOE SNPs with
changes in the lipid outcomes after Bonferroni correc-
tion (Tables 4, 5 and Additional file 1: Tables S1-S3).
At 16 weeks, after adjustment for age, sex, ethnicity and
baseline BMI, a significant interaction between the APOE
SNP rs1064725 and dietary intervention (SFA vs. MUFA vs.
n-6 PUFA) on changes in fasting total cholesterol (Pinteraction
= 0.001) was observed (Fig. 1). The ‘TT’ homozygotes (n=
108) of SNP rs1064725 had significantly lower total choles-
terol concentrations after the MUFA (n= 33; −0.71 ±Table 2 Genotype and minor allele frequencies of the SNPs at LPL and
SNP MAF Common homozygous N
LPL
rs320 (T > G) 0.30 56 (0.47)
rs328 (C > G) 0.13 89 (0.74)
APOE
rs405509 (G > T) 0.47 31 (0.25)
rs769450 (G > A) 0.37 44 (0.36)
rs439401 (C > T) 0.35 50 (0.42)
rs445925 (G > A) 0.11 91 (0.77)
rs405697 (G > A) 0.25 70 (0.58)
rs1160985 (C > T) 0.45 33 (0.27)
rs1064725 (T > G) 0.05 108 (0.90)
MAF minor allele frequency, LPL lipoprotein lipase, APOE apolipoprotein E1.88 mmol/l) compared with the SFA (n= 38; 0.34 ±
0.55 mmol/l; P= 0.003) and n-6 PUFA-rich diets (n= 37;
−0.08 ± 0.73 mmol/l; P= 0.15) (Passociation = 0.004) (Fig. 1).
In addition, we also observed an interaction between LPL
SNP rs320 and the dietary fat intervention (SFA vs. MUFA
vs n-6 PUFA) on changes in LDL-C concentrations after
16 weeks (Pinteraction = 0.005) (Table 5). In the n-6 PUFA
diet group, the G allele carriers (n = 19) of the LPL SNP
showed a reduction in LDL-C levels (−1.0 ± 2.51 mmol/l)
compared to the TT genotype (n = 24; 0.91 ± 2.23 mmol/l)
(Passociation = 0.007). However, this interaction was not sta-
tistically significant after correction for multiple testing.
None of the other SNPs showed a significant interaction on
changes in lipid concentrations after the 16-week dietary
intervention (Additional file 1: Tables S1-S3).
Discussion
To our knowledge, this is the first study to investigate the
effects of SNPs in both LPL and APOE genes on fasting
serum lipid response after substituting SFA with MUFA or
n-6 PUFA. Our findings from this retrospective analysis ofAPOE genes in the DIVAS cohort of adults with moderate CVD risk
(%) Heterozygous N (%) Rare homozygous N (%)
54 (0.45) 9 (0.07)
30 (0.25) 1 (0.008)
64 (0.53) 25 (0.20)
61 (0.50) 15 (0.12)
52 (0.44) 16 (0.13)
25 (0.21) 1 (0.008)
38 (0.31) 11 (0.09)
64 (0.53) 23 (0.19)
12 (0.10) –
Table 3 Baseline characteristics of the DIVAS study participants according to the LPL and APOE genotypes
SNP Age Sex (M/F) TAG (mmol/l) HDL-C (mmol/l) LDL-C (mmol/l) Total cholesterol (mmol/l)
LPL
rs320
TT 46 ± 9 27/29 1.28 ± 0.63 1.54 ± 0.41 3.73 ± 0.96 5.52 ± 1.15
T/G 48 ± 9 27/36 1.27 ± 0.57 1.53 ± 0.31 3.81 ± 1.01 5.59 ± 1.07
P value 0.83 0.41 0.71 0.53
rs328
CC 46 ± 9 42/47 1.29 ± 0.63 1.52 ± 0.37 3.72 ± 1.01 5.49 ± 1.17
C/G 48 ± 10 12/19 1.23 ± 0.47 1.58 ± 0.27 3.96 ± 0.88 5.79 ± 0.83
P value 0.51 0.93 0.42 0.49
APOE
rs405509
GG 47 ± 10 17/14 1.41 ± 0.63 1.42 ± 0.39 3.71 ± 1.01 5.41 ± 1.20
GT 47 ± 9 21/43 1.18 ± 0.57 1.58 ± 0.31 3.77 ± 1.00 5.58 ± 1.05
TT 45 ± 11 16/9 1.34 ± 0.61 1.55 ± 0.38 3.85 ± 0.94 5.67 ± 1.12
P value 0.57 0.24 0.81 0.70
rs769450
GG 47 ± 10 24/20 1.30 ± 0.61 1.57 ± 0.37 3.88 ± 0.96 5.71 ± 1.11
G/A 46 ± 9 30/46 1.25 ± 0.59 1.51 ± 0.34 3.71 ± 1.00 5.47 ± 1.10
P value 0.89 0.24 0.99 0.74
rs439401
CC 48 ± 9 25/25 1.37 ± 0.61 1.53 ± 0.36 3.88 ± 0.84 5.68 ± 0.95
T allele 46 ± 10 29/39 1.22 ± 0.59 1.53 ± 0.34 3.69 ± 1.07 5.47 ± 1.19
P value 0.43 0.95 0.54 0.54
rs445925
GG 46 ± 10 40/51 1.26 ± 0.58 1.53 ± 0.35 3.72 ± 1.00 5.50 ± 1.13
A allele 49 ± 8 13/13 1.36 ± 0.67 1.56 ± 0.38 3.97 ± 1.00 5.80 ± 1.04
P value 0.95 0.77 0.64 0.61
rs405697
GG 47 ± 9 35/35 1.32 ± 0.62 1.52 ± 0.39 3.77 ± 0.91 5.56 ± 1.01
A allele 46 ± 10 19/30 1.22 ± 0.57 1.55 ± 0.31 3.77 ± 1.08 5.56 ± 1.22
P value 0.77 0.91 0.95 0.95
rs1160985
CC 46 ± 11 17/16 1.24 ± 0.62 1.55 ± 0.34 3.73 ± 0.96 5.53 ± 1.11
CT 47 ± 8 24/40 1.27 ± 0.61 1.57 ± 0.33 3.87 ± 0.96 5.69 ± 1.02
TT 46 ± 11 13/10 1.35 ± 0.51 1.38 ± 0.40 3.57 ± 1.08 5.23 ± 1.30
P value 0.98 0.58 0.51 0.49
rs1064725
TT 47 ± 9 48/60 1.26 ± 0.59 1.55 ± 0.34 3.79 ± 1.00 5.59 ± 1.11
G allele 45 ± 10 6/6 1.40 ± 0.65 1.42 ± 0.46 3.60 ± 0.85 5.29 ± 1.00
P value 0.39 0.32 0.79 0.65
P values for association between genotypes and lipids levels were obtained by using general linear model adjusted for age, sex, body mass index, and ethnicity.
Values are mean ± SD
The dominant model was applied for all SNPs (rare homozygotes were grouped with heterozygotes and compared with common homozygotes), except SNPs
rs405509 and rs1160985 where additive model was applied (common homozygotes vs. heterozygotes vs. rare homozygotes)
TAG triacylglycerol, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, LPL lipoprotein lipase, APOE apolipoprotein E
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Table 4 Changes in lipid levels after dietary intervention over 16 weeks relative to baseline according to the APOE rs1064725 genotype
SFA MUFA n-6 PUFA Pinteraction
TT (N = 38) G allele (N = 3) P association TT (N = 33) G allele (N = 3) P association TT (N = 37) G allele (N = 6) P association
TAG 0.001 ± 1.76 0.22 ± 0.51 0.81 −0.01 ± 0.35 0.30 ± 0.32 0.15 −0.66 ± 2.05 0.04 ± 0.23 0.12 0.67
HDL-C 0.06 ± 1.70 −0.003 ± 0.14 0.87 0.003 ± 0.17 −0.06 ± 0.11 0.63 0.21 ± 2.08 0.20 ± 0.23 0.85 0.99
LDL-C 0.05 ± 1.48 2.90 ± 4.41 0.02 −0.55 ± 2.47 1.49 ± 2.70 0.27 −0.22 ± 2.24 1.99 ± 3.71 0.03 0.88
P values for association between genotypes and changes of means over 16 weeks with one of three diets were obtained by using general linear model adjusted
for age, sex, body mass index, and ethnicity. P values for interaction between genotypes and changes of means over 16 weeks of intervention with one of three
diets were obtained by using general linear model adjusted for age, sex, body mass index, and ethnicity. Values are mean ± SD
TAG triacylglycerol, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, SFA saturated fatty acids, MUFA monounsaturated fatty
acids, PUFA polyunsaturated fatty acids
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study population) at APOE SNP rs1064725 had significantly
lower total cholesterol concentrations after the 16-week re-
placement of SFA with MUFA in adults at moderate risk of
CVD. Our findings indicate a greater sensitivity of this
genotype group to dietary fat composition, particularly with
respect to replacement of SFA with MUFA, which may
have important public health implications.
Findings from cross-sectional studies are not adequate to
prove the beneficial impact of a dietary component on dis-
ease prevention; therefore, data from chronic dietary inter-
vention studies are preferable to detect changes in disease
biomarkers over a period of time [37]. A dietary intervention
study has shown a reduction of 51% in fasting total choles-
terol in non-diabetic adults with mild abdominal obesity after
two weeks of following a MUFA-rich diet (20% TE) com-
pared to a SFA-rich diet (19% TE) [38]. In support of the
beneficial effect of MUFA-rich olive oil, a Mediterranean diet
supplemented with extra-virgin olive oil for 4.8 years in older
adults has also been shown to reduce the incidence of major
CVD events [39], which suggests the potential role of MUFA
and/or nutraceuticals such as polyphenols found in extra-
virgin olive oil in the prevention of CVD-related outcomes
[40]. Our retrospective data analysis has demonstrated a sig-
nificant interaction between APOE SNP rs1064725 and a
MUFA-rich diet on total cholesterol levels in adults at mod-
erate CVD risk, where the MUFA-rich diet reduced fasting
total cholesterol in ‘TT’ homozygotes compared to the SFA-Table 5 Changes in lipid levels after dietary intervention over 16 we
SFA MUFA
TT
(N = 21)
G allele
(N = 20)
Passociation TT
(N = 11)
G allel
(N = 24
Total
cholesterol
0.37 ± 0.60 0.29 ± 0.45 0.59 0.21 ± 2.66 −0.67
TAG −0.04 ± 2.35 0.07 ± 0.59 0.84 0.04 ± 0.50 0.01 ±
HDL-C 0.09 ± 0.15 0.01 ± 2.33 0.94 −0.07 ± 0.17 0.03 ±
LDL-C 0.29 ± 2.71 0.27 ± 0.40 0.95 −1.70 ± 2.85 0.16 ±
P values for association between genotypes and changes of means over 16 weeks w
for age, sex, body mass index, and ethnicity. P values for interaction between geno
diets were obtained by using general linear model adjusted for age, sex, body mas
TAG triacylglycerol, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lip
acids, PUFA polyunsaturated fatty acidsand n-6 PUFA-rich diets. Our finding is in line with a previ-
ous study that also showed APOE genotypes to modulate
changes in plasma total cholesterol and LDL-C in healthy in-
dividuals after consuming MUFA- (22% TE, virgin olive oil),
SFA- (20% TE), and carbohydrate- (55% TE) rich diets for
4 weeks, where levels were higher in the E4/E3 carriers, inter-
mediate in E3/E3 carriers, and lower in E3/E2 carriers [24].
Another study showed that a MUFA-rich dietary interven-
tion (mainly olive oil) for 12 months increased the secretion
of TAG-rich lipoproteins (TRL) containing apoE and de-
creased the secretion of those without apoE. As a result, a
MUFA-rich diet shortened the residence time of very low
density lipoprotein (VLDL) particles in the circulation and in-
creased the direct clearance of TRL from the circulation (due
to the enrichment of TRLs with apoE, a ligand for receptor
mediated uptake), decreasing their conversion to LDLs [41].
Hence, it can be hypothesised that a MUFA-rich diet is likely
to regulate the clearance rate of TRL among ‘TT’ genotype
carriers of the APOE SNP rs1064725 via effects on TRL par-
ticle apolipoprotein composition. However, the underlying
mechanism of how the ‘TT’ genotype acts differently from
the ‘G’ allele on TRL metabolism in response to a MUFA-
rich diet remains unclear and requires further investigation.
In our study, the common LPL SNP rs320 was found to
modify the association between the n-6 PUFA-rich diet with
changes in LDL-C levels, where the ‘G’ allele carriers had a
tendency for a greater reduction in LDL-C concentrations
compared to TT homozygotes. As far as the authors areeks according to LPL rs320 genotypes
n-6 PUFA Pinteraction
e
)
Passociation TT (N = 24) G allele
(N = 19)
Passociation
± 2.07 0.21 −0.32 ± 1.67 −0.12 ± 0.64 0.92 0.34
0.29 0.58 −0.07 ± 0.32 −1.19 ± 2.78 0.02 0.15
0.15 0.04 0.02 ± 0.25 0.43 ± 2.91 0.78 0.75
2.22 0.11 0.91 ± 2.23 −1.00 ± 2.50 0.007 0.005
ith one of three diets were obtained by using general linear model adjusted
types and changes of means over 16 weeks of intervention with one of three
s index, and ethnicity. Values are mean ± SD
oprotein cholesterol, SFA saturated fatty acids, MUFA monounsaturated fatty
Fig. 1 Mean (±SE) of changes in total cholesterol concentrations following three intervention diets [rich in either saturated fatty acids (SFA),
monounsaturated fatty acids (MUFA), and n-6 polyunsaturated fatty acids (PUFA)] according to the APOE SNP rs1064725 genotype (Pinteraction =
0.001). A general linear model analysis was performed with adjustments for age, sex, body mass index, and ethnicity. Individuals carrying the ‘TT’
genotype had lower total cholesterol levels after consuming the MUFA diet compared to the SFA or n-6 PUFA diets (Passociation = 0.004)
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with, except for one which showed that minor allele (‘G’)
carriers of LPL SNP rs328 had lower fasting TAG concen-
trations when the participants had n-6 PUFA intake below
35.48% of total fat (below 35.48% of total fat median intake
of LIPGENE study population) [19]. Besides LPL, evidence
also suggests that the genetic effect of SNPs in APOA5
and TNFA on lipid metabolism is modulated by n-6 PUFA
[42, 43]. In mice, n-6 PUFA intake has been shown to play
a role in the upregulation of genes encoding proteins in-
volved in adipogenesis [44]. Thus, dietary n-6 PUFA may
upregulate LPL gene expression and/or activity, leading to
lower circulating lipid concentrations [19, 45]. In addition
to the role of LPL in hydrolysing TRL, LPL plays a role in
binding TRL (i.e. VLDL) to hepatic LDL receptors, which
help to mediate the clearance of these particles [46]. This
leads to a reduced conversion of VLDL to LDL, resulting
in lower plasma LDL-C levels [47]. Even though the inter-
action between the LPL SNP rs320 and n-6 PUFA-rich
diet on LDL-C concentrations in the current data analysis
was not statistically significant after Bonferroni correction,
which could be due to the small sample size, further large
studies are required to explore this gene-diet interaction.
Statistically significant interactions were demonstrated in
this study, however there are some limitations. The sample
size was relatively small for some of the genotype groups as
the genotyping was performed retrospectively, and investiga-
tion of the lipid response according to APOE and LPL SNPs
was not the main objective of the DIVAS study. Compared
with cross-sectional studies, randomized clinical trials are
conducted with smaller sample sizes. In our study, only 120
participants out of 195 consented to genetic analysis and
hence this resulted in a small sample size for the analysis.However, we were able to identify significant gene-diet inter-
actions on total cholesterol even after Bonferroni correction.
Thus, this hypothesis testing analysis has identified the need
for suitably-powered dietary intervention trials using pro-
spective genotyping to investigate the impact of dietary fat
composition on plasma lipid responses according to APOE
genotypes. A selection bias may also have existed because
the participants were multi-ethnic (Asian 7% and Black 7%).
However, to reduce this potential confounding effect, the
analyses were adjusted for ethnicity. Furthermore, the inter-
action between SNP rs1064725 at APOE and the interven-
tion diets on total cholesterol was still significant (P= 0.003)
even after excluding other ethnic groups from the analysis
(data not shown). One of the main strengths of our study
was that it examined the effects of three types of dietary fat
(isoenergetically) consumed for a long duration (16 weeks)
on lipid phenotypes in a robust randomised controlled inter-
vention study, which addressed current dietary fat recom-
mendations. Furthermore, we used a tagSNP approach
whereby all the genetic variations in the APOE gene
have been investigated in this study.
Conclusion
In conclusion, our study shows an interaction between
APOE SNP rs1064725 and dietary fat intake on fasting total
cholesterol concentrations, suggesting a greater sensitivity
of the ‘TT’ homozygotes (90%) to dietary fat composition,
with a total cholesterol lowering effect observed following
substitution of SFA with MUFA but not with n-6 PUFA.
However, given that the present study was conducted in a
relatively small group of individuals, further large studies
using prospective genotyping are required to confirm our
findings.
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